CERTIFICATE OF MAILING OCT 1 7 2002 hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to

Attorney Docket No.: R-126

Ssistant Commissioner for Patents

Washington, D.C., 20231

DELTAGEN, INC.

RECEIVED

00T 2 1 2002 TECH CENTER 1600:2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

CATHERINE GUENTHER et al.

Application No.: 09/883,093

Filed: June 14, 2001

For: Transgenic Mice Containing Nuclear

Hormone Receptor Gene Disruptions

Examiner:

Unassigned

Art Unit:

1646


SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37

CFR §1.97 and §1.98

Assistant Commissioner for Patents Washington, D.C. 20231

The references cited on attached Form PTO/SB/08A are being called to the attention of Sir: the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

This Information Disclosure Statement as far as is known to the undersigned, is filed before the mailing date of a first Office Action on the merits. Each item contained in the information disclosure statement was cited in an International Search Report (copy enclosed) mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.



While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR § 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR § 1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR § 1.98 and MPEP § 609 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is hereby authorized to charge our Deposit Account No. 50-1271 for any fees required in connection with the filing of this Information Disclosure Statement. A duplicate copy of this Notice is enclosed for this purpose. In particular, in the event that an Office Action has crossed in the mail with this Information Disclosure Statement, the Commissioner is authorized to charge the above-named deposit account for any fees required pursuant to CFR § 1.17(p) or § 1.17(i)(1).

Respectfully submitted,

Mariette A. Lapiz, Reg. No. 44,202

DELTAGEN, INC. 740 Bay Road

Redwood City, CA 94063

Tel: 650-569-5100 Fax: 650-569-5280

MAL/dam

PTO SB. 08A (10-01)

Approved for use through 10.31 2002 OMB 0651-0031

U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE order the Paperwork Beduction Act of 1995, no persons are required to respond to a collection of information unless if contains a valid OMB control bumber.

INFORMATION DISCLOSURE

Substitute for form 1449A PTO

OCT 1 7 2002

ENTS THA

STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 1

	Complete if Known	RECEIVED
Application Number	09/883,093	
Filing Date	June 14, 2001	UCH 2.1 2002
First Named Inventor	GUENTHER	
Art Unit	1646	FECH CENTER 1600/2
Examiner Name	Unassigned	TEUT CENTER 1000
Attorney Docket Number	R-126	

		U.S. PATENT DO	CUMENTS	
	Document Number	Publication Data Issue Data	Name of Retented or	Pages, Columns, Lines, Where
Cite No	Number Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
Α	US-5,650,550	07/ 22/1997	KORACH et al.	
		_		
	No	Cite No Number Kind Code ² (if known)	Cite No Number Kind Code ² (# known) Publication Date/Issue Date MM-DD-YYYY	Cite Number Kind Code ² (# known) Publication Date/Issue Date Name of Patentee or Applicant of Cited Document

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document			Name of Patentee or	Pages, Columns, Lines,	T	
		Country Code ³	Number ⁴	Code ⁵ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T⁵
	В٠	WO	96/35785	A2	11/14/1996	KARO BIO AB	Claims 1, 7, 8	
	C ·	wo	94/26100	A1	11/24/1994	INST. NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE et al.	Claim 1	
•	D ·	WO	01/51045	A2	07/19/2001	TULARIK INC.	Example 6	
	Ε	WO	02/25270	A1	03/28/2002	BAYLOR COLLEGE OF MEDICINE	Claims 3-5	
	F	WO	99/15555	A1	04/01/1999	THE GENERAL HOSPITAL CORP.	Claims 1, 3	
					-			<u> </u>
								L

Examiner Signature	Date Considered	

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Officer, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include copy of this form with next communication to applicant

Applicant's unique citation designation number (optional). See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.